research Virtual screening of MAP-Tau protein inhibitors from Semecarpus anacardium Linn. leaf extract for cancer prevention
Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.
Search
for
Sort by
Research
390-420 / 1000+ results research The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
research YAP and TAZ are essential for basal and squamous cell carcinoma initiation
YAP and TAZ proteins are necessary for the development of two types of skin cancer.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
research NF-κB in biology and targeted therapy: new insights and translational implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research 700 Tyrosine kinase 2 inhibition rescues hair follicles from IL-12–mediated immune privilege collapse and reverses the induction of human alopecia areata in a humanized mouse model
Inhibiting TYK2 can restore hair growth in alopecia areata.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
research 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research KRT17: A Key Driver of Cancer Therapy Resistance and Emerging Therapeutic Target
Targeting Keratin 17 may help overcome cancer therapy resistance.
research Nilontinib induced keratosis pilaris atrophicans
Nilotinib can cause skin issues like red bumps and hair loss.
research Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Lack of KSR1 stops certain skin tumors in mice.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Hinokitiol, a Natural Tropolone Derivative, Inhibits TNF-α Production in LPS-Activated Macrophages via Suppression of NF-κB
Hinokitiol may help treat hair loss by reducing inflammation and promoting hair growth.
research 557 Short-term Rho-associated kinase inhibitor treatment accelerates primary keratinocyte growth without affecting the characteristics of the stem cell population
Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Drugs that block GSK-3 show promise for treating various diseases.
research Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
research Janus kinase inhibitors: An innovative treatment for alopecia areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.